Moreover, the response to TKIs varies among lung cancer patients with KRAS mutations and may be affected by such factors as coexistence of mutations in tumor suppressor genes (TP53 or PTEN) [31, 32]. This evidence concerns the gene TP53 and lung carcinoma.